Novatim, a strategic partner of AsymBio, announced U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the world's 𝗳𝗶𝗿𝘀𝘁 𝗔𝗗𝗖 with a 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗻𝗮𝗻𝗼𝗯𝗼𝗱𝘆 targeting MET and EGFR. With this IND approval, Novatim will be able to conduct phase 1 clinical trials in US for patients with advanced solid tumors. 

We look forward to continuing our collaboration to advance clinical trials and address unmet medical needs for patients worldwide.